BDTX
Black Diamond Therapeutics, Inc
$2.99
+9.93%
2026-05-08
About Black Diamond Therapeutics, Inc
Black Diamond Therapeutics, Inc., a clinical-stage oncology company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is silevertinib, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in Phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as Phase 2 clinical trial to treat glioblastoma. It is also developing BDTX-4933, a brain-penetrant RAF MasterKey inhibitor targeting KRAS, NRAS, and BRAF alterations in solid tumors that is in Phase 1 clinical trial. In addition, the company is developing BDTX-4876, a MasterKey inhibitor of oncogenic FGFR2/3 mutations with selectivity versus FGFR1/4, which is in preclinical stage. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
Key Fundamentals
P/E Ratio
6.65
Forward P/E
-2.77
EPS (TTM)
$-0.77
ROE
22.9%
Profit Margin
32.0%
Debt/Equity
16.74
Price/Book
1.42
Beta
3.35
Market Cap
$159.3M
Avg Volume (10D)
890K
Recent Breakout Signals
No recent breakout signals detected for BDTX.
Recent Price Range (60 Days)
60D High
$3.43
60D Low
$1.93
Avg Volume
725K
Latest Close
$2.99
Get breakout alerts for BDTX
Sign up for Breakout Scanner to receive daily notifications when BDTX triggers breakout signals. Build custom AI screeners and backtest strategies.
Start Free Trial7-day free trial. No card required.
Black Diamond Therapeutics, Inc (BDTX) is listed on the NASDAQ (NASDAQ). Breakout Scanner monitors BDTX daily for breakout patterns including long-term ceiling breakouts, momentum breakouts, and near-breakout watch setups. BDTX operates in the Healthcare sector within the Biotechnology industry. Data is provided for informational purposes only and does not constitute financial advice.